Blocking the survival of the nastiest by HSP90 inhibition
作者： Paul Workman , Paul A. Clarke , Bissan Al-Lazikani
关键词:
摘要: It is now recognised that genetic, epigenetic and phenotypic heterogeneity within individual human cancers responsible for therapeutic resistance - knowledge having a profound impact on current thinking experimentation. There has been concern molecularly targeted therapy doomed to failure, with resistant clones emerging in response the Darwinian selective pressure of any drug treatment. However, two studies have shown evolution can be restrained by co-administration pharmacologic inhibitor HSP90 molecular chaperone.
core.ac.uk
impactjournals.com参考文章(7)
P. Nowell, The clonal evolution of tumor cell populations Science. ,vol. 194, pp. 23- 28 ,(1976) , 10.1126/SCIENCE.959840
Mel Greaves, Carlo C. Maley, Clonal evolution in cancer Nature. ,vol. 481, pp. 306- 313 ,(2012) , 10.1038/NATURE10762
Luke Whitesell, Sandro Santagata, Marc L. Mendillo, Nancy U. Lin, David A. Proia, Susan Lindquist, HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models Proceedings of the National Academy of Sciences of the United States of America. ,vol. 111, pp. 18297- 18302 ,(2014) , 10.1073/PNAS.1421323111
Bissan Al-Lazikani, Udai Banerji, Paul Workman, Combinatorial drug therapy for cancer in the post-genomic era Nature Biotechnology. ,vol. 30, pp. 679- 692 ,(2012) , 10.1038/NBT.2284
Len Neckers, Paul Workman, Hsp90 molecular chaperone inhibitors: are we there yet? Clinical Cancer Research. ,vol. 18, pp. 64- 76 ,(2012) , 10.1158/1078-0432.CCR-11-1000
Marco Gerlinger, Nicholas McGranahan, Sally M. Dewhurst, Rebecca A. Burrell, Ian Tomlinson, Charles Swanton, Cancer: Evolution Within a Lifetime Annual Review of Genetics. ,vol. 48, pp. 215- 236 ,(2014) , 10.1146/ANNUREV-GENET-120213-092314
Tomoko Smyth, Kim H.T. Paraiso, Keisha Hearn, Ana M. Rodriguez-Lopez, Joanne M. Munck, H. Eirik Haarberg, Vernon K. Sondak, Neil T. Thompson, Mohammad Azab, John F. Lyons, Keiran S.M. Smalley, Nicola G. Wallis, Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models Molecular Cancer Therapeutics. ,vol. 13, pp. 2793- 2804 ,(2014) , 10.1158/1535-7163.MCT-14-0452